THE SIGNIFICANCE OF POMEGRANATE PEEL AS AN ADJUNCT PHYTOTHERAPEUTIC AGENT IN THE MANAGEMENT OF LIVER DISEASES

Authors

  • Tadjibayeva Mohinur Abduvohid kizi Department of Biological Chemistry, Andijan State Medical Institute Andijan, Uzbekistan Author

Keywords:

Keywords: Pomegranate peel, Punica granatum, liver diseases, metabolic dysfunction-associated steatotic liver disease, oxidative stress, punicalagin, ellagic acid, phytotherapy.

Abstract

Abstract. Liver diseases, particularly metabolic dysfunction-associated steatotic liver disease, chronic liver injury following viral hepatitis, toxic hepatopathies, and fibrotic liver disorders, remain important challenges in modern medicine. In recent years, plant-derived products rich in natural polyphenols have attracted scientific attention because of their potential to reduce oxidative stress, inflammation, and lipid metabolic disturbances in hepatocytes. Pomegranate peel contains biologically active compounds such as punicalagin, ellagic acid, gallic acid, flavonoids, and tannins, which have demonstrated antioxidant, anti-inflammatory, antifibrotic, and metabolic regulatory properties in experimental studies and a limited number of clinical trials. The purpose of this article is to analyze the possible significance of pomegranate peel in the management of liver diseases on the basis of current scientific literature, to describe its biochemical mechanisms, and to evaluate the limitations of its clinical use. The literature suggests that pomegranate peel extract should not be considered an independent treatment for liver diseases. Rather, it may be studied as an adjunct to standard dietary modification, physical activity, control of metabolic risk factors, and etiological treatment.

References

1.Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023). AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), 1797–1835.

2.European Association for the Study of the Liver, European Association for the Study of Diabetes, & European Association for the Study of Obesity. (2024). EASL–EASD–EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology, 81(3), 492–542.

3.Mo, Y., Ma, J., Gao, W., Zhang, L., Li, J., Li, J., Zang, J., & Li, X. (2022). Pomegranate peel as a source of bioactive compounds. Frontiers in Nutrition, 9, 887113.

4.Venusova, E., Kolesarova, A., Horky, P., & Slama, P. (2021). Physiological and immune functions of punicalagin. Nutrients, 13(7), 2150.

5.Wei, X., Fang, R., Yang, Y., Bi, X., Ren, G., Luo, A., Zhao, M., & Zang, W. (2015). Protective effects of extracts from pomegranate peels and seeds on liver fibrosis induced by carbon tetrachloride in rats. BMC Complementary and Alternative Medicine, 15, 389.

6.Ahmad, N., Shahzad, A., & Khan, M. R. (2016). Amelioration of acetaminophen induced hepatotoxicity by pomegranate peel extract. Pakistan Journal of Pharmaceutical Sciences, 29(2), 397–402.

7.Barghchi, H., Milkarizi, N., Belyani, S., Norouzian Ostad, A., Askari, V. R., Rajabzadeh, F., Goshayeshi, L., Ghelichi Kheyrabadi, S. Y., Razavidarmian, M., Dehnavi, Z., Sobhani, S. R., & Nematy, M. (2023). Pomegranate peel extract ameliorates metabolic syndrome risk factors in patients with non-alcoholic fatty liver disease. Nutrition Journal, 22, 40.

8.Baghdadi, G., Shidfar, F., Mokhtare, M., & colleagues. (2025). Effect of pomegranate peel consumption on liver enzymes, lipid profile, liver steatosis, and hs-CRP in patients with non-alcoholic fatty liver disease. Phytotherapy Research, 39(2), 619–629.

9.European Association for the Study of the Liver. (2019). EASL clinical practice guidelines on drug-induced liver injury. Journal of Hepatology, 70(6), 1222–1261.

10.Xu, J., Cao, K., Liu, X., Zhao, L., Feng, Z., Liu, J., & Cheng, Y. (2021). Punicalagin regulates signaling pathways in inflammation-associated chronic diseases. Molecules, 27(1), 1–20.

11.Lv, O., Wang, L., Li, J., Ma, Q., & Zhao, W. (2016). Effects of pomegranate peel polyphenols on lipid accumulation and cholesterol metabolic transformation in human hepatic cells. Food & Function, 7(12), 4976–4983.

12.Bahari, H., Ramezani-Jolfaie, N., Mohammadi, M., & colleagues. (2024). The effects of pomegranate consumption on liver function in adults. Phytotherapy Research, 38(2), 635–648.

13.Sharifi-Rad, J., Quispe, C., Castillo, C. M. S., Caroca, R., Lazo-Vélez, M. A., Antonyak, H., Polishchuk, A., Lysiuk, R., Oliinyk, P., De Masi, L., & colleagues. (2022). Ellagic acid, a review on its natural sources, chemical stability, and therapeutic potential. Oxidative Medicine and Cellular Longevity, 2022, 3848084.

14.Ali, H., Khan, T., Ullah, R., & colleagues. (2021). Hepatoprotective potential of pomegranate in curbing the carbon tetrachloride-induced oxidative stress and liver damage. Evidence-Based Complementary and Alternative Medicine, 2021, 6666782.

15.Pfohl, M., Lin, Y., Pignitter, M., & colleagues. (2021). Hepatoprotective and anti-inflammatory effects of a standardized pomegranate fruit extract in high-fat diet-induced obese mice. International Journal of Food Sciences and Nutrition, 72(4), 499–510.

Downloads

Published

2026-06-09